HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Catalent, Inc

Geron’s Potential Blockbuster Imetelstat Faces Unexpected AdComm In MDS

Geron’s highly anticipated telomerase inhibitor has been given a user fee date by the US Food and Drug Administration next year and will also be subject to an advisory committee meeting, despite largely positive analyst sentiment on clinical results to date.

Advisory Committees Companies

Geron’s Imetelstat Headed To US FDA Advisory Committee For MDS

Geron’s telomerase inhibitor will also get standard review for transfusion-dependent anemia in adults with low- to intermediate-1 risk myelodysplastic syndromes (MDS), suggesting FDA reviewers may be less bullish on imetelstat’s clinical data than analysts have been.

Advisory Committees Drug Review

UPDATED: Regeneron Wins Same-Day Veopoz, High-Dose Eylea US FDA Approvals

Veopoz (pozelimab) approval showed the FDA was reassured that Regeneron’s contract manufacturer is ready to supply high-dose Eylea, a key product for the company as competition picks up.

Approvals Rare Diseases

Regeneron Raises Possibility Of Quick CRL Resolution For High-Dose Eylea

On its Q2 earnings call, Regeneron said its 8mg formulation of aflibercept could obtain US FDA approval this quarter, despite receiving a complete response letter in June. Refiling’s fate tied to review of pozelimab.

Business Strategies Complete Response Letters
See All

Company Information

  • Industry
  • Contract Research, Toxicology Testing-CRO
  • Services
  • Pharmaceuticals
    • OTC, Consumer
    • Drug Delivery
      • Controlled Release
      • Macromolecule
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Synthesis Technologies, Production Processes
  • Other Names / Subsidiaries
    • Accucaps Industries Limited
    • Catalent U.K. Swindon Zydis Limited
    • Cook Pharmica LLC
    • Juniper Pharmaceuticals
    • Molecular Profiles Ltd.
    • Columbia Laboratories, Inc.
UsernamePublicRestriction

Register